The UBQLN2 antibody is a crucial tool for studying the ubiquitin-like protein UBQLN2. which plays a vital role in cellular protein quality control. UBQLN2 facilitates the degradation of misfolded or damaged proteins by shuttling them to the proteasome and autophagy pathways via its ubiquitin-associated (UBA) and ubiquitin-like (UBL) domains. Mutations in the UBQLN2 gene are genetically linked to neurodegenerative disorders, particularly amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD), often associated with abnormal protein aggregates like TDP-43. Researchers use UBQLN2 antibodies in techniques such as Western blotting, immunohistochemistry, and immunofluorescence to investigate its expression, localization, and interactions in healthy and diseased tissues. These studies aim to elucidate how UBQLN2 dysfunction contributes to neurodegeneration, including impaired protein clearance, stress granule dynamics, and autophagy-lysosomal pathway defects. UBQLN2 antibodies also help identify pathological hallmarks in animal models and patient samples, advancing our understanding of disease mechanisms. Their application extends to exploring therapeutic strategies targeting UBQLN2-related pathways to mitigate protein aggregation and neuronal loss. Overall, UBQLN2 antibodies are indispensable for unraveling the molecular basis of ALS/FTD and developing potential biomarkers or treatments.